Literature DB >> 33381317

Matrix Metalloproteinases MMP-2 and MMP-9 Occupy a New Role in Severe Preeclampsia.

Elena Timokhina1, Alexander Strizhakov1, Sapiyat Ibragimova1, Evgeny Gitel2, Irina Ignatko1, Vera Belousova1, Nikoleta Zafiridi1.   

Abstract

INTRODUCTION: Preeclampsia (PE) is a life-threatening condition for the mother, the fetus, and the newborn. Matrix metalloproteinases (MMP) participate in the two primary stages of PE: remodeling of blood vessels at the stage of placental formation and the development of hypertension due to damage to the basement membrane of blood vessels. The object of the present study was to reveal the role of MMP-2 and MMP-9 in the development of severe preeclampsia.
MATERIALS AND METHODS: We conducted a retrospective study that included 92 pregnant women at a gestational age of 26-38 weeks, of which the principal group consisted of 61 patients with severe PE. We divided the principal group into two subgroups: the first subgroup was designated the severe early-onset preeclampsia (EO-PE) group and consisted of 30 pregnant women. The second group was designated the severe late-onset preeclampsia (LO-PE) group, comprising 31 patients. We determined the plasma concentrations of MMPs 2 and 9 in the groups with an ELISA.
RESULTS: In the group of PE patients with both EO-PE and LO-PE, the level of MMP-2 was significantly higher compared to the women undergoing normal pregnancy; and we observed no significant differences when we compared the levels of MMP-2 in the subgroups with EO-PE and LO-PE. Analysis of the concentrations of MMP-9 in EO-PE and LO-PE subgroups revealed attenuated levels of MMP-9 in both groups relative to the control group. We also noted a diminished level of MMP-9 in the EO-PE group compared to the LO-PE group.
CONCLUSIONS: The significantly increased levels of MMP-2 in women-both in the EO-PE and LO severe PE subgroups-explain the participation of this enzyme in endothelial dysfunction in the second stage of severe PE. A diminution in MMP-9 in the EO-PE group confirmed the participation of MMP-9 in the process of spiral artery transformation.
Copyright © 2020 Elena Timokhina et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33381317      PMCID: PMC7759403          DOI: 10.1155/2020/8369645

Source DB:  PubMed          Journal:  J Pregnancy        ISSN: 2090-2727


  14 in total

Review 1.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

2.  Altered protease expression by periarterial trophoblast cells in severe early-onset preeclampsia with IUGR.

Authors:  Frank Reister; John C P Kingdom; Peter Ruck; Klaus Marzusch; Wolfgang Heyl; Uli Pauer; Peter Kaufmann; Werner Rath; Berthold Huppertz
Journal:  J Perinat Med       Date:  2006       Impact factor: 1.901

3.  Matrix metalloproteinase-9 gene -1562C/T polymorphism mitigates preeclampsia.

Authors:  M Coolman; M de Maat; W L Van Heerde; L Felida; S Schoormans; E A P Steegers; R M Bertina; C J M de Groot
Journal:  Placenta       Date:  2006-11-28       Impact factor: 3.481

4.  Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia.

Authors:  H Narumiya; Y Zhang; C Fernandez-Patron; L J Guilbert; S T Davidge
Journal:  Hypertens Pregnancy       Date:  2001       Impact factor: 2.108

5.  Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

Authors:  Raquel F Gerlach; Caroline Demacq; Klaus Jung; Jose E Tanus-Santos
Journal:  Clin Biochem       Date:  2006-10-19       Impact factor: 3.281

Review 6.  Biochemical and Biological Attributes of Matrix Metalloproteinases.

Authors:  Ning Cui; Min Hu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-03-22       Impact factor: 3.622

7.  Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy.

Authors:  Martina Montagnana; Giuseppe Lippi; Alessandro Albiero; Silvia Scevarolli; Gian Luca Salvagno; Massimo Franchi; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

8.  Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.

Authors:  Ana C T Palei; Valeria C Sandrim; Ricardo C Cavalli; Jose E Tanus-Santos
Journal:  Clin Biochem       Date:  2008-04-26       Impact factor: 3.281

9.  First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.

Authors:  Leona C Y Poon; Ekaterina Nekrasova; Panagiotis Anastassopoulos; Panagiotis Livanos; Kypros H Nicolaides
Journal:  Prenat Diagn       Date:  2009-06       Impact factor: 3.050

Review 10.  New Insights into the Role of Matrix Metalloproteinases in Preeclampsia.

Authors:  Salvador Espino Y Sosa; Arturo Flores-Pliego; Aurora Espejel-Nuñez; Diana Medina-Bastidas; Felipe Vadillo-Ortega; Veronica Zaga-Clavellina; Guadalupe Estrada-Gutierrez
Journal:  Int J Mol Sci       Date:  2017-07-20       Impact factor: 5.923

View more
  2 in total

1.  The Efficacy Mechanism of Epigallocatechin Gallate against Pre-Eclampsia based on Network Pharmacology and Molecular Docking.

Authors:  Xinru Gao; Jiahao Wang; Jiamiao Shi; Qinru Sun; Ning Jia; Hui Li
Journal:  Reprod Sci       Date:  2022-02-24       Impact factor: 3.060

Review 2.  Insight into the Key Points of Preeclampsia Pathophysiology: Uterine Artery Remodeling and the Role of MicroRNAs.

Authors:  Katarzyna Pankiewicz; Anna Fijałkowska; Tadeusz Issat; Tomasz M Maciejewski
Journal:  Int J Mol Sci       Date:  2021-03-19       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.